American Century Companies’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

American Century Companies’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-34,173	Closed	-$532K	–	1391
2017 Q3	$532K	Buy	34,173 +1,933	+6%	+$27.3K	﹤0.01%	1223
2017 Q2	$452K	Sell	32,240 -2,646	-8%	-$56.6K	﹤0.01%	1244
2017 Q1	$767K	Buy	+34,886	New	+$739K	﹤0.01%	1171

Other funds holding JNCE

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

American Century Companies's JNCE Position: Q4 2017 in Review

American Century Companies sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2017, closing a stake of 34,173 shares — an estimated $532K sold.

American Century Companies first reported a position in JNCE in Q1 2017 and held it in 3 quarters. The position peaked at $767K in Q1 2017. 83 funds tracked by Wall St. Rank hold JNCE as of Q4 2017.

American Century Companies reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
American Century Companies sold 34,173 Jounce Therapeutics, Inc. Common Stock shares in Q4 2017, an estimated $532K.
American Century Companies first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 3 quarters.
American Century Companies's Jounce Therapeutics, Inc. Common Stock position peaked at $767K in Q1 2017.
83 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2017.

Based on American Century Companies's 13F filing for Q4 2017, filed 2 Feb 2018.